What is Cryo-Cell International Inc.'s earnings per share (EPS)?

Cryo-Cell International Inc. (CCEL) reported diluted earnings per share of -$0.30 for fiscal year 2025. This represents a -700.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cryo-Cell International Inc. (CCEL) Financials

CCEL

Trailing 12 months to August 31, 2026

Revenue $31.1M -2.0% YoY

Net Income -$1.9M -310.8% YoY

EPS (Diluted) -$0.23 -283.3% YoY

Free Cash Flow $4.7M -24.8% YoY

Market Cap $35.2M as of Oct 9, 2026

Price / Sales 1.1x on $31.1M revenue, trailing 12 months to August 31, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to August 31, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Aug 31, 2026 Reported Oct 9, 2026 Currency USD FYE November

Newest figures come from the 10-Q for Q3 FY2026, filed Oct 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CCEL SEC filings page.

Cryo-Cell International Inc. (CCEL) reported $31.1M in revenue over the twelve months to Aug 31, 2026, down 2.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CCEL FY2025 2026-10-03

Revenue is stable and gross margins are improving, but overhead, interest, and a liability-heavy balance sheet keep earnings fragile.

Gross margin rose from 73.2% in FY2023 to 76.6% in FY2025, but that improvement did not restore operating profitability. With revenue roughly $31M in both years, the issue is not scale-driven expansion; higher gross profit is being absorbed by operating costs and financing expense.

FY2025 produced a net loss of $2.4M alongside operating cash flow of $5.5M, so accounting earnings understated cash generation. Because capital spending was only $230K, most operating cash remained as free cash flow of $5.2M, indicating unusually light reinvestment that year.

FY2025 liabilities were $80.3M versus $61.7M of assets, leaving negative equity of $18.6M and making the capital structure liability-funded rather than equity-funded. A current ratio of 0.6x also indicates that current assets did not cover current liabilities, while the negative equity makes conventional debt-to-equity interpretation less useful.

Financial Health Signals

Financial Health Score 27/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Cryo-Cell International Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Cryo-Cell International Inc. has an operating margin of 1.5%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 19/100, suggesting thin profitability after operating expenses. This is down from 10.9% the prior year.

Growth

Cryo-Cell International Inc.'s revenue declined 1.3% year-over-year, from $32.0M to $31.6M. This contraction results in a growth score of 32/100.

Leverage

Liquidity

Cryo-Cell International Inc.'s current ratio of 0.59 is below the typical benchmark, resulting in a score of 6/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

Cryo-Cell International Inc. converts 16.6% of revenue into free cash flow ($5.2M). This strong cash generation earns a score of 74/100.

Returns

Altman Z-Score Distress

-0.23

Cryo-Cell International Inc. scores -0.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($35.2M) relative to total liabilities ($80.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

6/9

Cryo-Cell International Inc. passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

N/A

Cryo-Cell International Inc. reported a net loss of $2.4M while generating $5.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk

0.23x

Cryo-Cell International Inc. earns $0.23 in operating income for every $1 of interest expense ($482K vs $2.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$7.8M

YoY0.0%

QoQ+0.6%

5Y CAGR+0.8%

10Y CAGR+2.1%

Cryo-Cell International Inc. generated $7.8M in revenue in Q3 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is up 0.6%.

EBITDA

$2.4M

YoY+14.0%

QoQ+72.1%

5Y CAGR+5.0%

Cryo-Cell International Inc.'s EBITDA was $2.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.0% from the same quarter a year earlier. Against the prior quarter it is up 72.1%.

Net Income

$1.3M

YoY+69.5%

QoQ+129.1%

5Y CAGR+8.2%

Cryo-Cell International Inc. reported $1.3M in net income in Q3 2026. This represents an increase of 69.5% from the same quarter a year earlier. Against the prior quarter it is up 129.1%.

EPS (Diluted)

$0.16

YoY+77.8%

QoQ+128.6%

5Y CAGR+9.9%

Cryo-Cell International Inc. earned $0.16 per diluted share (EPS) in Q3 2026. This represents an increase of 77.8% from the same quarter a year earlier. Against the prior quarter it is up 128.6%.

Cash & Balance Sheet

Free Cash Flow

$1.0M

YoY-58.4%

QoQ-42.6%

5Y CAGR+14.5%

10Y CAGR-0.3%

Cryo-Cell International Inc. generated $1.0M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 58.4% from the same quarter a year earlier. Against the prior quarter it is down 42.6%.

Cash & Debt

$1.4M

YoY+437.6%

QoQ+181.0%

5Y CAGR-28.6%

10Y CAGR-3.5%

Cryo-Cell International Inc. held $1.4M in cash against $8.2M in long-term debt as of Q3 2026.

Shares Outstanding

YoY+0.1%

QoQ0.0%

5Y CAGR-1.1%

10Y CAGR+1.7%

Cryo-Cell International Inc. had 8M shares outstanding in Q3 2026. This represents an increase of 0.1% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin

79.4%

YoY+2.4pp

QoQ+0.9pp

5Y change+12.1pp

Cryo-Cell International Inc.'s gross margin was 79.4% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 2.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.9 percentage points.

Operating Margin

28.0%

YoY+3.7pp

QoQ+12.6pp

5Y change+6.8pp

10Y change+44.8pp

Cryo-Cell International Inc.'s operating margin was 28.0% in Q3 2026, reflecting core business profitability. This is up 3.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.6 percentage points.

Net Margin

16.2%

YoY+6.7pp

QoQ+9.1pp

5Y change+4.8pp

10Y change+58.0pp

Cryo-Cell International Inc.'s net profit margin was 16.2% in Q3 2026, showing the share of revenue converted to profit. This is up 6.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.1 percentage points.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending

$54K

YoY-13.0%

QoQ-46.3%

5Y CAGR+39.9%

10Y CAGR+14.6%

Cryo-Cell International Inc. invested $54K in research and development in Q3 2026. This represents a decrease of 13.0% from the same quarter a year earlier. Against the prior quarter it is down 46.3%.

Share Buybacks

YoY-100.0%

Cryo-Cell International Inc. repurchased no shares in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Capital Expenditures

$102K

YoY+162.7%

QoQ+211.5%

5Y CAGR-41.8%

10Y CAGR+32.0%

Cryo-Cell International Inc. invested $102K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 162.7% from the same quarter a year earlier. Against the prior quarter it is up 211.5%.

CCEL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CCEL quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$31.1M	$31.6M-1.3%	$32.0M+2.0%	$31.3M+3.3%	$30.3M+5.0%	$28.9M-7.3%	$31.1M-2.1%	$31.8M+8.9%	$29.2M+15.1%	$25.4M+9.8%	$23.1M+9.7%	$21.1M+4.8%	$20.1M+6.0%	$19.0M+5.7%	$18.0M+0.3%	$17.9M
Cost of Revenue	$6.7M	$7.4M-7.2%	$7.9M-5.3%	$8.4M-4.6%	$8.8M-2.2%	$9.0M-6.9%	$9.7M-3.8%	$10.0M+17.5%	$8.5M+27.0%	$6.7M	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$24.4M	$24.2M+0.6%	$24.0M+4.7%	$23.0M+6.5%	$21.5M+8.3%	$19.9M-7.4%	$21.5M-1.3%	$21.8M+5.3%	$20.7M+10.8%	$18.7M	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$304K	$376K-69.7%	$1.2M+6.1%	$1.2M+204.4%	$385K+671.6%	$50K+109.1%	$24K-20.9%	$30K-67.2%	$92K+123.1%	$41K-22.5%	$53K+16.0%	$46K-28.9%	$64K+78.0%	$36K-67.0%	$110K-40.4%	$184K
SG&A Expenses	$18.9M	$18.2M-1.6%	$18.5M+7.9%	$17.2M+10.2%	$15.6M+6.6%	$14.6M+2.2%	$14.3M-4.0%	$14.9M-4.7%	$15.6M+16.0%	$13.5M-8.4%	$14.7M+18.8%	$12.4M+1.1%	$12.3M+7.8%	$11.4M-21.2%	$14.4M+16.2%	$12.4M
Operating Income	$189K	$482K-86.1%	$3.5M+128.3%	-$12.3M-405.7%	$4.0M+0.2%	$4.0M-47.6%	$7.7M+51.3%	$5.1M-2.4%	$5.2M+3.7%	$5.0M+1054.6%	$434K-85.2%	$2.9M+48.1%	$2.0M+16.4%	$1.7M+199.5%	-$1.7M-518.3%	-$277K
EBITDA	N/A	$1.5M-64.8%	$4.2M+138.3%	-$10.9M-297.4%	$5.5M+9.2%	$5.1M-37.0%	$8.0M+47.0%	$5.5M-0.8%	$5.5M+7.2%	$5.1M+773.4%	$588K-80.6%	$3.0M+40.5%	$2.2M+13.8%	$1.9M+225.5%	-$1.5M-1883.6%	$84K
Interest Expense	$1.8M	$2.1M+10.8%	$1.9M+50.8%	$1.2M-18.7%	$1.5M+10.4%	$1.4M-10.7%	$1.5M-9.4%	$1.7M+10.1%	$1.5M+18.8%	$1.3M+37.5%	$947K-27.3%	$1.3M+13.2%	$1.2M-17.8%	$1.4M+37.0%	$1.0M-29.8%	$1.5M
Income Tax	$37K	$92K-96.2%	$2.4M+162.5%	-$3.8M-801.8%	$548K+3.8%	$528K-62.7%	$1.4M+28.5%	$1.1M-75.4%	$4.5M+241.8%	$1.3M+212.9%	-$1.2M+83.8%	-$7.2M-5893.8%	$124K-27.2%	$170K-91.0%	$1.9M+998.2%	$172K
Net Income	-$1.9M	-$2.4M-704.2%	$402K+104.2%	-$9.5M-443.6%	$2.8M+33.0%	$2.1M-42.5%	$3.6M+58.2%	$2.3M+368.0%	-$855K-136.9%	$2.3M+275.3%	-$1.3M-116.3%	$8.1M+1364.2%	$554K+1917.9%	$27K+100.4%	-$6.3M-201.0%	-$2.1M
EPS (Basic)	N/A	-$0.30-700.0%	$0.05+104.4%	-$1.14-445.5%	$0.33+26.9%	$0.26-45.8%	$0.48+65.5%	$0.29+363.6%	-$0.11-133.3%	$0.33+306.3%	-$0.16-118.8%	$0.85+1600.0%	$0.05	$0.00+100.0%	-$0.56-211.1%	-$0.18
EPS (Diluted)	-$0.23	-$0.30-700.0%	$0.05+104.4%	-$1.14-445.5%	$0.33+32.0%	$0.25-44.4%	$0.45+66.7%	$0.27+345.5%	-$0.11-136.7%	$0.30+287.5%	-$0.16-119.3%	$0.83+1560.0%	$0.05	$0.00+100.0%	-$0.56-211.1%	-$0.18
Diluted Shares (Avg)	N/A	8M-1.8%	8M-1.5%	8M-1.7%	8M+1.5%	8M+2.7%	8M-3.2%	8M+12.7%	7M-2.5%	8M-5.7%	8M-17.2%	10M-6.1%	10M-5.0%	11M-3.0%	11M-3.9%	12M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$7.8M0.0%	$7.8M-1.9%	$7.7M-3.6%	$7.8M-2.3%	$7.8M-3.0%	$7.9M-1.4%	$8.0M+1.5%	$8.0M+1.9%
Cost of Revenue	$1.6M-10.4%	$1.7M-9.7%	$1.7M-16.5%	$1.7M+0.2%	$1.8M-15.3%	$1.9M-8.3%	$2.0M-4.0%	$1.7M-14.5%
Gross Profit	$6.2M+3.1%	$6.1M+0.4%	$6.0M+0.7%	$6.1M-2.9%	$6.0M+1.4%	$6.1M+0.9%	$6.0M+3.4%	$6.3M+7.5%
R&D Expenses	$54K-13.0%	$100K-24.2%	$66K-33.0%	$85K-72.2%	$62K-68.2%	$132K-45.4%	$98K-80.5%	$305K-31.4%
SG&A Expenses	$3.8M-2.5%	$4.6M+8.5%	$5.0M+8.1%	$5.4M-7.9%	$3.9M-6.9%	$4.3M+6.0%	$4.6M+4.7%	$5.9M+8.6%
Operating Income	$2.2M+15.4%	$1.2M-19.8%	$765K-27.5%	-$4.0M-3142.2%	$1.9M+36.7%	$1.5M+7.3%	$1.1M+28.6%	-$122K+99.2%
EBITDA	$2.4M+14.0%	$1.4M-17.9%	$1.0M-22.6%	-$3.6M-1660.1%	$2.1M+31.7%	$1.7M+15.9%	$1.3M+43.7%	$231K+101.5%
Interest Expense	$438K-18.6%	$442K-19.8%	$463K-6.5%	$482K-35.4%	$538K+0.9%	$551K+67.4%	$495K+93.0%	$745K+541.0%
Income Tax	$555K+27.1%	$273K+24.6%	$23K-90.8%	-$815K-179.9%	$437K+33.0%	$219K-73.1%	$251K+5.3%	$1.0M+121.2%
Net Income	$1.3M+69.5%	$555K+55.9%	$47K-83.3%	-$3.8M-105.1%	$749K-28.7%	$356K-45.7%	$283K-49.1%	-$1.9M+83.4%
EPS (Basic)	$0.16+77.8%	$0.07+75.0%	$0.01-66.7%	-$0.47-104.3%	$0.09-30.8%	$0.04-50.0%	$0.03-57.1%	-$0.23+82.8%
EPS (Diluted)	$0.16+77.8%	$0.07+75.0%	$0.01	-$0.47-113.6%	$0.09-30.8%	$0.04-50.0%	$0.03-57.1%	-$0.22+83.6%
Diluted Shares (Avg)	8M-0.1%	8M-0.9%	8M	N/A	8M-1.2%	8M-1.3%	8M-1.5%	N/A

CCEL Balance Sheet

CCEL quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$61.7M-4.6%	$64.7M0.0%	$64.7M-0.3%	$64.9M+7.0%	$60.7M+31.3%	$46.2M+7.7%	$42.9M0.0%	$42.9M+79.4%	$23.9M+22.4%	$19.5M+0.2%	$19.5M+91.0%	$10.2M-11.2%	$11.5M-6.7%	$12.3M-36.7%	$19.5M
Current Assets	$11.8M-6.3%	$12.6M+32.8%	$9.5M-1.6%	$9.6M-39.1%	$15.8M-14.9%	$18.6M+20.6%	$15.4M+4.3%	$14.8M+15.9%	$12.7M+41.3%	$9.0M-13.0%	$10.4M+21.9%	$8.5M-10.3%	$9.5M+1.6%	$9.3M-33.7%	$14.1M
Cash & Equivalents	$319K-43.1%	$561K+38.1%	$406K-76.2%	$1.7M-79.4%	$8.3M-20.2%	$10.4M+58.4%	$6.5M+8.3%	$6.0M-3.8%	$6.3M+79.4%	$3.5M-15.7%	$4.2M+26.6%	$3.3M-16.5%	$3.9M+46.6%	$2.7M-57.5%	$6.3M
Short-Term Investments	$3.0M+1.4%	$2.9M+411.2%	$574K+3158.7%	$18K-76.6%	$75K-14.8%	$88K-90.2%	$904K+3.2%	$876K+99.3%	$439K-29.6%	$624K+2.3%	$610K+494.5%	$103K+170.8%	$38K	$0-100.0%	$1.0M
Inventory	$409K-37.8%	$658K-14.5%	$769K-9.7%	$851K-7.6%	$921K-0.7%	$927K-14.5%	$1.1M-14.0%	$1.3M+300.7%	$315K-12.9%	$361K-24.1%	$476K+646.1%	$64K	N/A	N/A	N/A
Accounts Receivable	$6.8M-6.3%	$7.3M+11.1%	$6.6M+8.8%	$6.0M+15.1%	$5.3M-16.9%	$6.3M+3.7%	$6.1M+3.9%	$5.9M+14.5%	$5.1M+26.5%	$4.1M+32.5%	$3.1M-24.9%	$4.1M+22.0%	$3.3M+17.6%	$2.8M-7.3%	$3.1M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$38K+177.5%	$14K+113.3%	$6K
Goodwill	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M	$0	$0-100.0%	$1.8M	$0	N/A	N/A	N/A
Total Liabilities	$80.3M+3.1%	$77.9M+7.8%	$72.3M+8.8%	$66.4M+17.6%	$56.5M+15.6%	$48.9M-2.0%	$49.8M-2.8%	$51.3M+40.9%	$36.4M+4.2%	$35.0M+42.9%	$24.5M+16.8%	$20.9M+0.8%	$20.8M-2.6%	$21.3M-2.7%	$21.9M
Current Liabilities	$19.8M-8.4%	$21.6M+3.5%	$20.9M+7.1%	$19.5M-7.6%	$21.1M+28.4%	$16.4M+6.4%	$15.4M0.0%	$15.4M+10.7%	$13.9M+6.3%	$13.1M+25.8%	$10.4M+14.2%	$9.1M-7.0%	$9.8M-8.0%	$10.7M+1.0%	$10.6M
Non-Current Liabilities	$60.5M+7.5%	$56.3M+9.5%	$51.4M+9.5%	$46.9M+32.6%	$35.4M+9.1%	$32.5M-5.7%	$34.4M-4.1%	$35.9M+59.6%	$22.5M+2.9%	$21.8M+55.6%	$14.0M+18.9%	$11.8M+7.8%	$11.0M+2.8%	$10.7M-6.2%	$11.4M
Long-Term Debt	$8.4M-1.5%	$8.5M-1.3%	$8.6M-1.5%	$8.7M+360.0%	$1.9M-68.1%	$5.9M-33.7%	$9.0M+528.5%	$1.4M0.0%	$1.4M0.0%	$1.4M-38.0%	$2.3M0.0%	$2.3M0.0%	$2.3M0.0%	$2.3M-19.3%	$2.9M
Total Equity	-$18.6M-40.8%	-$13.2M-19.8%	-$11.0M-623.7%	-$1.5M-136.4%	$4.2M+257.0%	-$2.7M+61.7%	-$7.0M+22.0%	-$8.9M+28.8%	-$12.5M+18.9%	-$15.4M-210.5%	-$5.0M+53.7%	-$10.7M-15.7%	-$9.3M-3.0%	-$9.0M-265.7%	-$2.5M
Retained Earnings	-$38.4M-17.3%	-$32.8M-5.2%	-$31.2M-44.0%	-$21.6M-29.3%	-$16.7M+11.1%	-$18.8M+16.1%	-$22.4M+11.4%	-$25.3M-3.5%	-$24.5M+8.6%	-$26.8M-5.2%	-$25.5M+24.1%	-$33.6M+0.4%	-$33.7M+0.1%	-$33.8M-23.0%	-$27.4M

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$62.3M-1.4%	$60.7M-5.8%	$60.9M-5.4%	$61.7M-4.6%	$63.2M+0.4%	$64.4M+3.0%	$64.4M+4.3%	$64.7M0.0%
Current Assets	$13.2M+12.8%	$11.3M-13.4%	$11.1M-11.4%	$11.8M-6.3%	$11.7M+9.5%	$13.1M+28.5%	$12.5M+32.3%	$12.6M+32.8%
Cash & Equivalents	$1.4M+437.6%	$507K+269.0%	$250K+11.9%	$319K-43.1%	$265K+34.3%	$137K-70.7%	$223K-9.7%	$561K+38.1%
Short-Term Investments	$2.8M-5.2%	$2.7M-38.2%	$2.7M-18.6%	$3.0M+1.4%	$3.0M+53.2%	$4.3M+304.9%	$3.3M+344.6%	$2.9M+411.2%
Inventory	$534K-18.6%	$310K-54.2%	$357K-51.1%	$409K-37.8%	$655K-10.4%	$677K-4.4%	$730K-3.3%	$658K-14.5%
Accounts Receivable	$6.8M0.0%	$6.9M-0.3%	$6.8M-5.5%	$6.8M-6.3%	$6.8M-0.6%	$6.9M+1.5%	$7.2M+7.2%	$7.3M+11.1%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%	$1.9M0.0%
Total Liabilities	$78.7M+0.9%	$78.5M-1.9%	$79.3M+0.3%	$80.3M+3.1%	$78.0M+7.6%	$80.0M+9.1%	$79.0M+9.7%	$77.9M+7.8%
Current Liabilities	$15.3M-16.9%	$15.9M-26.8%	$17.8M-18.2%	$19.8M-8.4%	$18.5M+5.9%	$21.8M+11.8%	$21.7M+12.1%	$21.6M+3.5%
Non-Current Liabilities	$63.4M+6.4%	$62.5M+7.4%	$61.5M+7.3%	$60.5M+7.5%	$59.5M+8.1%	$58.2M+8.1%	$57.3M+8.8%	$56.3M+9.5%
Long-Term Debt	$8.2M-1.7%	$8.3M-1.7%	$8.3M-1.6%	$8.4M-1.5%	$8.4M-1.4%	$8.4M-1.3%	$8.5M-1.3%	$8.5M-1.3%
Total Equity	-$16.4M-10.5%	-$17.8M-14.1%	-$18.4M-25.5%	-$18.6M-40.8%	-$14.8M-55.2%	-$15.6M-44.9%	-$14.7M-41.8%	-$13.2M-19.8%
Retained Earnings	-$36.6M-5.6%	-$37.8M-7.0%	-$38.4M-11.2%	-$38.4M-17.3%	-$34.6M-19.8%	-$35.4M-18.1%	-$34.5M-12.8%	-$32.8M-5.2%

CCEL Cash Flow Statement

CCEL quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$4.9M	$5.5M-8.9%	$6.0M-32.6%	$8.9M+4.0%	$8.6M+8.2%	$7.9M-6.4%	$8.5M+34.5%	$6.3M+18.0%	$5.3M-6.7%	$5.7M+14.6%	$5.0M+2.8%	$4.9M+212.0%	$1.6M+89.2%	$822K+127.8%	$361K-55.9%	$819K
Depreciation & Amortization	N/A	$985K+42.0%	$694K-50.4%	$1.4M-6.6%	$1.5M+44.2%	$1.0M+179.1%	$372K-7.2%	$401K+26.5%	$317K+141.1%	$132K-14.9%	$155K+67.9%	$92K-46.2%	$171K-8.9%	$188K-7.8%	$204K-43.5%	$361K
Stock-Based Compensation	N/A	$417K-46.6%	$781K-4.3%	$817K+77.0%	$461K+53.0%	$302K-51.5%	$622K+56.4%	$398K-16.9%	$478K-50.8%	$972K-45.2%	$1.8M+193.9%	$603K+49.2%	$404K+48.6%	$272K-79.5%	$1.3M+302.8%	$329K
Capital Expenditures	$269K	$230K-90.4%	$2.4M-64.9%	$6.8M-43.8%	$12.2M+563.5%	$1.8M+1734.7%	$100K-84.9%	$662K+48.4%	$446K+353.7%	$98K-71.3%	$343K+216.2%	$108K-10.0%	$121K-65.5%	$350K+161.9%	$134K-73.6%	$506K
Free Cash Flow	$4.7M	$5.2M+45.5%	$3.6M+73.4%	$2.1M+157.9%	-$3.6M-159.0%	$6.1M-27.2%	$8.4M+48.5%	$5.6M+15.3%	$4.9M-13.0%	$5.6M+21.0%	$4.6M-2.1%	$4.7M+230.7%	$1.4M+203.8%	$472K+107.7%	$227K-27.5%	$313K
Investing Cash Flow	-$416K	-$975K+80.0%	-$4.9M+40.1%	-$8.1M+46.7%	-$15.3M-119.8%	-$7.0M-2044.5%	$357K+154.0%	-$662K+94.1%	-$11.3M-12228.4%	$93K	N/A	N/A	N/A	$1.1M+19.4%	$962K+132.5%	-$3.0M
Financing Cash Flow	-$3.3M	-$4.7M-384.6%	-$979K+52.8%	-$2.1M-1501.9%	$148K+104.8%	-$3.1M+38.6%	-$5.0M+2.5%	-$5.1M-189.9%	$5.7M+288.3%	-$3.0M	N/A	N/A	N/A	-$724K+85.4%	-$5.0M-6217.1%	$81K
Dividends Paid	$0	$3.2M+59.9%	$2.0M	$0-100.0%	$7.7M	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$170K-88.1%	$1.4M+78.2%	$799K-56.1%	$1.8M+629.8%	$249K	N/A	$992K	N/A	$447K-95.9%	$10.8M+237.1%	$3.2M+20.0%	$2.7M+261.6%	$739K-56.6%	$1.7M	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	$1.1M-55.0%	$1.8M+161.1%	$652K-31.7%	$1.3M-40.6%	$2.5M+4.1%	$707K-60.1%	$954K+367.3%	$2.2M-35.5%
Depreciation & Amortization	$184K-0.7%	$184K-3.0%	$244K-1.5%	$243K-2.4%	$186K-4.6%	$190K+217.9%	$248K+188.2%	$249K-25.9%
Stock-Based Compensation	$93K+151.5%	$64K+60.0%	$159K-46.7%	N/A	$37K-74.8%	$40K-77.5%	$297K-3.2%	N/A
Capital Expenditures	$102K+162.7%	$33K-47.6%	$67K+8.1%	$67K+705.3%	$39K-79.1%	$62K-96.4%	$62K-86.4%	$8K-99.5%
Free Cash Flow	$1.0M-58.4%	$1.8M+181.3%	$585K-34.4%	$1.2M-43.5%	$2.5M+10.9%	$645K+2891.3%	$892K+209.5%	$2.1M+31.9%
Investing Cash Flow	-$181K-116.4%	$35K+102.3%	$19K+106.6%	-$290K+74.0%	$1.1M+266.0%	-$1.5M+45.4%	-$287K+15.7%	-$1.1M+43.7%
Financing Cash Flow	-$43K+98.8%	-$1.6M-328.6%	-$740K+26.3%	-$937K-38.3%	-$3.5M-71.9%	$710K-41.0%	-$1.0M-286.4%	-$678K+56.0%
Dividends Paid	$0	$0-100.0%	$0-100.0%	$0-100.0%	$0	$1.2M	$2.0M	$2.0M
Share Buybacks	$0-100.0%	N/A	N/A	$0	$81K+393.2%	$89K-92.8%	$0-100.0%	$0

CCEL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CCEL quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	76.6%+1.5pp	75.1%+1.9pp	73.2%+2.2pp	71.0%+2.1pp	68.9%-0.1pp	69.0%+0.5pp	68.5%-2.3pp	70.8%-2.7pp	73.5%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	1.5%-9.3pp	10.9%+50.1pp	-39.3%-52.5pp	13.3%-0.6pp	13.9%-10.7pp	24.6%+8.7pp	15.9%-1.9pp	17.8%-2.0pp	19.7%+17.8pp	1.9%-12.0pp	13.9%+4.1pp	9.8%+0.9pp	9.0%+18.5pp	-9.5%-8.0pp	-1.5%
Net Margin	-7.7%-9.0pp	1.3%+31.6pp	-30.4%-39.5pp	9.1%+1.9pp	7.2%-4.4pp	11.6%+4.4pp	7.2%+10.1pp	-2.9%-12.0pp	9.1%+14.8pp	-5.7%-44.1pp	38.4%+35.7pp	2.8%+2.6pp	0.1%+35.3pp	-35.1%-23.4pp	-11.7%
Return on Equity	N/A	N/A	N/A	N/A	49.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-3.9%-4.6pp	0.6%+15.3pp	-14.7%-19.0pp	4.3%+0.8pp	3.4%-4.4pp	7.8%+2.5pp	5.3%+7.3pp	-2.0%-11.7pp	9.7%+16.4pp	-6.8%-48.3pp	41.6%+36.2pp	5.4%+5.2pp	0.2%+51.4pp	-51.2%-40.4pp	-10.8%
Current Ratio	0.590.0x	0.58+0.1x	0.450.0x	0.49-0.3x	0.75-0.4x	1.13+0.1x	1.000.0x	0.960.0x	0.91+0.2x	0.69-0.3x	0.99+0.1x	0.930.0x	0.96+0.1x	0.87-0.5x	1.33
Debt-to-Equity	N/A	N/A	N/A	N/A	0.45	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Asset Turnover	0.510.0x	0.490.0x	0.480.0x	0.470.0x	0.48-0.2x	0.67-0.1x	0.74+0.1x	0.68-0.4x	1.06-0.1x	1.18+0.1x	1.08-0.9x	1.97+0.3x	1.65+0.2x	1.46+0.5x	0.92
FCF Margin	16.6%+5.4pp	11.3%+4.6pp	6.6%+18.5pp	-11.8%-32.9pp	21.1%-5.8pp	26.9%+9.2pp	17.7%+1.0pp	16.7%-5.4pp	22.1%+2.1pp	20.1%-2.4pp	22.5%+15.4pp	7.1%+4.6pp	2.5%+1.2pp	1.3%-0.5pp	1.8%

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Gross Margin	79.4%+2.4pp	78.4%+1.9pp	78.4%+3.3pp	77.9%-0.5pp	77.0%+3.3pp	76.6%+1.8pp	75.1%+1.4pp	78.4%+4.1pp
Operating Margin	28.0%+3.7pp	15.4%-3.4pp	10.0%-3.3pp	-50.6%-49.1pp	24.3%+7.1pp	18.8%+1.5pp	13.3%+2.8pp	-1.5%
Net Margin	16.2%+6.7pp	7.1%+2.6pp	0.6%-2.9pp	-48.7%-25.5pp	9.6%-3.5pp	4.5%-3.7pp	3.5%-3.5pp	-23.2%
Return on Assets	2.0%+0.9pp	0.9%+0.4pp	0.1%-0.4pp	-6.2%-3.3pp	1.2%-0.5pp	0.5%-0.5pp	0.4%-0.5pp	-2.9%+14.4pp
Current Ratio	0.86+0.2x	0.71+0.1x	0.620.0x	0.590.0x	0.630.0x	0.60+0.1x	0.58+0.1x	0.58+0.1x
Asset Turnover	0.130.0x	0.130.0x	0.130.0x	0.130.0x	0.120.0x	0.120.0x	0.120.0x	0.120.0x
FCF Margin	13.3%-18.6pp	23.3%+15.2pp	7.6%-3.6pp	15.5%-11.3pp	31.9%+4.0pp	8.1%+7.9pp	11.2%+21.6pp	26.8%+6.1pp

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.

Note: Shareholder equity is negative (-$18.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.59), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Cryo-Cell International Inc. CCEL	FY2025	$31.6M	-$2.4M	-7.7%	$35.2M	27/100
Basel Medical Group Ltd BMGL	FY2025	$8.9M	-$8.4M	-94.0%	$5.2M	17/100
Concord Medical Services Holding Limited CCM	FY2025	$65.9M	-$13.3M	-20.2%	$13.6M	29/100
American Shared Hospital Services AMS	FY2025	$28.1M	-$1.6M	-5.5%	$9.0M	37/100
NewGenIvf Group Limited NIVF	FY2025	$4.7M	$9.9M	N/A	$2.9M	31/100
ModivCare Inc. MODV	FY2024	$2.8B	-$201.3M	-7.2%	$6.2M	20/100

Where Cryo-Cell International Inc. Ranks

Frequently Asked Questions

What is Cryo-Cell International Inc.'s annual revenue?

Cryo-Cell International Inc. (CCEL) reported $31.6M in total revenue for fiscal year 2025. This represents a -1.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cryo-Cell International Inc.'s revenue growing?

Cryo-Cell International Inc. (CCEL) revenue declined by 1.3% year-over-year, from $32.0M to $31.6M in fiscal year 2025.

Is Cryo-Cell International Inc. profitable?

No, Cryo-Cell International Inc. (CCEL) reported a net income of -$2.4M in fiscal year 2025, with a net profit margin of -7.7%.

What is Cryo-Cell International Inc.'s EBITDA?

Cryo-Cell International Inc. (CCEL) had EBITDA of $1.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Cryo-Cell International Inc. have?

As of fiscal year 2025, Cryo-Cell International Inc. (CCEL) had $319K in cash and equivalents against $8.4M in long-term debt.

What is Cryo-Cell International Inc.'s gross margin?

Cryo-Cell International Inc. (CCEL) had a gross margin of 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Cryo-Cell International Inc.'s operating margin?

Cryo-Cell International Inc. (CCEL) had an operating margin of 1.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Cryo-Cell International Inc.'s net profit margin?

Cryo-Cell International Inc. (CCEL) had a net profit margin of -7.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Cryo-Cell International Inc.'s free cash flow?

Cryo-Cell International Inc. (CCEL) generated $5.2M in free cash flow during fiscal year 2025. This represents a 45.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cryo-Cell International Inc.'s operating cash flow?

Cryo-Cell International Inc. (CCEL) generated $5.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Cryo-Cell International Inc.'s total assets?

Cryo-Cell International Inc. (CCEL) had $61.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cryo-Cell International Inc.'s capital expenditures?

Cryo-Cell International Inc. (CCEL) invested $230K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Cryo-Cell International Inc. spend on research and development?

Cryo-Cell International Inc. (CCEL) invested $376K in research and development during fiscal year 2025.

Does Cryo-Cell International Inc. buy back shares?

Yes, Cryo-Cell International Inc. (CCEL) spent $170K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Cryo-Cell International Inc. have outstanding?

Cryo-Cell International Inc. (CCEL) had 8M shares outstanding as of fiscal year 2025.

What is Cryo-Cell International Inc.'s current ratio?

Cryo-Cell International Inc. (CCEL) had a current ratio of 0.59 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Cryo-Cell International Inc.'s return on assets (ROA)?

Cryo-Cell International Inc. (CCEL) had a return on assets of -3.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cryo-Cell International Inc.'s P/E ratio?

Cryo-Cell International Inc. (CCEL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to August 31, 2026). The market capitalization is $35.2M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Cryo-Cell International Inc.'s price-to-sales ratio?

Cryo-Cell International Inc. (CCEL) trades at 1.1x sales, its market capitalization divided by revenue of $31.1M revenue, trailing 12 months to August 31, 2026. The market capitalization is $35.2M as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is Cryo-Cell International Inc.'s debt-to-equity ratio negative or not reported?

Cryo-Cell International Inc. (CCEL) has negative shareholder equity of -$18.6M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Cryo-Cell International Inc.'s Altman Z-Score?

Cryo-Cell International Inc. (CCEL) has an Altman Z-Score of -0.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Cryo-Cell International Inc.'s Piotroski F-Score?

Cryo-Cell International Inc. (CCEL) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cryo-Cell International Inc.'s earnings high quality?

Cryo-Cell International Inc. (CCEL) reported a net loss of $2.4M while generating $5.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Cryo-Cell International Inc. cover its interest payments?

Cryo-Cell International Inc. (CCEL) has an interest coverage ratio of 0.23x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Cryo-Cell International Inc.?

Cryo-Cell International Inc. (CCEL) scores 27 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.